We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $15K invested in ELITE PHARMACEUTICAL in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $13K → $15K (+$2K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q1 2021 in Review

2 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2021, worth a combined $15K — up 15% from $13K a quarter earlier.

Fund positioning in ELI was balanced in Q1 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $15K of ELITE PHARMACEUTICAL stock for Q1 2021, up 15% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q1 2021 and 0 closed out.

Based on aggregated 13F filings for Q1 2021.